Beverly Hills, California (PRWEB) March 17, 2015

Beverly Hills Orthopedic Institute is now offering stem cell procedures for the nonoperative treatment of shoulder labral tears. The procedures are outpatient, low risk, and very effective at helping patients avoid the need for surgery. Call Beverly Hills Orthopedic Institute at (310) 247-0466 for more information and scheduling.

Injuries to the shoulder may involve rotator cuff tendonitis, tears or labral injury. Stem cell therapy is typically effective for all of these conditions, and Dr. Raj has been having significant success with labral tears. Conventional treatment for labral tears is often unsuccessful, as they typically do not have sufficient blood supply.

Treatment with regenerative medicine offers the potential to avoid surgery and heal the tissues. The stem cell therapy includes either bone marrow or amniotic derived treatment. Both of these are outpatient and very low risk. Small studies have shown the effectiveness of stem cell treatment for joint arthritis, tendonitis, tendon tears, cartilage defects and labral tears.

The treating physician, Dr. Raj, is a Double Board Certified orthopedic surgeon Beverly Hills trusts, and excels in treating all kinds of sports injuries and arthritic conditions. He also serves as a Medical Correspondent for ABC News, along with receiving numerous LA TOP DOC and Top Doctors Southern California Awards.

To receive the best stem cell therapy in Los Angeles and Beverly Hills, call the Institute today at (310) 247-0466.

Read more from the original source:
Beverly Hills Orthopedic Institute Now Offering Stem Cell Therapy for Nonoperative Shoulder Labral Tears

Recommendation and review posted by Bethany Smith

Christopher Jewell, an assistant professor in the University of Maryland Fischell Department of Bioengineering, was awarded a three-year, $250,000 grant from the Alliance for Cancer Gene Therapy to develop gene therapy to promote cancer immunity, the university and the alliance announced Monday.

Jewell's research could create vaccine "depots" among the lymph nodes, specialized tissues that control responses against disease and infection.

The alliance is a nonprofit that sponsors promising research into cell and gene therapies to battle cancer. Jewell is one of two grant recipients this year and among 46 since 2001 from the alliance, which has a goal of replacing radiation, chemotherapy and surgery, while turning cancer into a manageable, treatable disease.

The Stamford, Conn.-based group has handed out more than $25 million in funding for the cause.

Go here to see the original:
Maryland researcher wins grant to study alternative cancer therapy

Recommendation and review posted by Bethany Smith

Stamford, CT (PRWEB) March 16, 2015

Alliance for Cancer Gene Therapy (ACGT) the nations only nonprofit dedicated exclusively to cell and gene therapies for cancer has achieved a major milestone, surpassing $25 million donated to innovative and breakthrough cancer research. ACGT was founded by Barbara Netter and her late husband, Edward, in 2001 with the goal of transforming cancer into a manageable, treatable disease.

Pushing the foundation across the $25 million threshold are a pair of three-year, $250,000 grants to two esteemed scientists: Meenakshi Hegde, MD, of Texas Childrens Cancer Center at Baylor College of Medicine in Houston, TX, and Christopher Jewell, PhD, at University of Maryland, College Park. Dr. Hegdes work will focus on immunotherapy, specifically adoptive cellular therapy for melanoma. Dr. Jewells research is centered on harnessing intra-lymph node gene therapy to promote tumor immunity. The grantees will develop genetically-modified T cells and cancer vaccines with the potential to stop cancer in its tracks.

Drs. Hegde and Jewell are two outstanding scientists in the vanguard of treating and defeating cancer, said Barbara Netter, ACGTs President. Their work offers tremendous hope to those battling cancer, and also to their loved ones.

ACGT grants are awarded to promising researchers whose work dovetails with the foundations mission: Leveraging cell and gene therapies to supplant the more harrowing cancer treatments like radiation, chemotherapy and surgery. ACGTs $25 million in grants have funded watershed research and trials such as those that activate patients own immune systems to battle cancer cells. These trials have saved the lives of cancer patients otherwise believed to be beyond treatment.

The two most recent grants continue ACGTs mission of equipping innovative scientists with the tools and support to revolutionize the fight against cancer. ACGT grants range from $250,000 to $1 million, and reward both young, promising researchers and their more established colleagues. Past recipients include such pre-eminent scientists as University of Pennsylvanias Dr. Carl June and Memorial Sloan-Ketterings Dr. Michel Sadelain; this past summer, the Food and Drug Administration (FDA) granted breakthrough status to immunotherapy treatments for leukemia developed by each of these scientists for which ACGT provided early funding.

About Alliance for Cancer Gene Therapy (ACGT) Established in 2001, ACGT (http://www.acgtfoundation.org) is the nations only not-for-profit dedicated exclusively to cell and gene therapy treatments for all types of cancer. One-hundred percent of contributions go directly to research. ACGT has funded 46 grants in the U.S. and Canada since its founding in 2001 by Barbara Netter, President, and her late husband, Edward, to conduct and accelerate critically needed innovative research. Since its inception, ACGT has awarded 31 grants to Young Investigators and 15 grants to Clinical Investigators, totaling more than $25 million in funding. ACGT is located at 96 Cummings Point Road, Stamford, CT 06902.

ACGT on Facebook: http://www.facebook.com/ACGTfoundation ACGT on Twitter: http://www.twitter.com/ACGTfoundation ACGT on YouTube: http://www.youtube.com/user/ACGTfoundation

Read the original:
ACGT Surpasses $25 Million Funding Milestone with Two New Grants

Recommendation and review posted by Bethany Smith

Researchers have identified a new host of gene variants that could make people vulnerable to sporadic motor neurone disease, according to a report published today in the journal, Scientific Reports.

Until recently, it was thought that genetics made little contribution to the disease - also termed amyotrophic lateral sclerosis (ALS) - and that the environment was mostly to blame.

Motor neurone disease (MND) is a group of diseases in which the nerve cells in the brain and spinal cord controlling the muscles that enable us to move, speak, breathe and swallow to slowly degenerate and die.

Currently two to three thousand Australians are living with this fatal disease.

Death is caused by respiratory failure, which typically occurs within 2 to 5 years of developing this debilitating condition.

MND is also the subject of a major research program at the University of Sydney's Brain and Mind Research Institute.

Awareness of MND has spiked in recent times due to the social media campaign supporting the 'Ice Bucket Challenge', and the Oscar winning biopic about cosmologist Stephen Hawking, The Theory of Everything.

"This is an advance in knowledge about the role genetics is likely to play in sporadic forms of motor neurone disease," says the University of Sydney's Associate Professor Roger Pamphlett, a co-author of the new study.

'Sporadic' motor neurone disease accounts for about 90 per cent of cases. It refers to random, isolated cases in which individuals have no known risk factors or family history of the disease.

"The findings indicate that the genetic changes underlying many cases of sporadic motor neurone disease could stem from one of two sources," Associate Professor Pamphlett says.

View original post here:
Motor Neurone Disease - researchers identify new group of gene suspects

Recommendation and review posted by Bethany Smith

Genetic Engineering: Advantages Disadvantages
via YouTube Capture.

By: Seamus Edwards

Read the original here:
Genetic Engineering: Advantages & Disadvantages - Video

Recommendation and review posted by Bethany Smith

Genetic Engineering: ethical and moral issues
via YouTube Capture.

By: Seamus Edwards

Continued here:
Genetic Engineering: ethical and moral issues - Video

Recommendation and review posted by Bethany Smith

Genetic Engineering: How does it work
via YouTube Capture.

By: Seamus Edwards

See more here:
Genetic Engineering: How does it work - Video

Recommendation and review posted by Bethany Smith

University of Illinois College of Agricultural, Consumer and Environmental Sciences

URBANA - University of Illinois scientists have engineered a "jailbreaking" yeast that could greatly increase the health benefits of wine while reducing the toxic byproducts that cause your morning-after headache.

"Fermented foods--such as beer, wine, and bread--are made with polyploid strains of yeast, which means they contain multiple copies of genes in the genome. Until now, it's been very difficult to do genetic engineering in polyploid strains because if you altered a gene in one copy of the genome, an unaltered copy would correct the one that had been changed," said Yong-Su Jin, a U of I associate professor of microbial genomics and principal investigator in the Energy Biosciences Institute.

Recently scientists have developed a "genome knife" that cuts across multiple copies of a target gene in the genome very precisely--until all copies are cut. Jin's group has now used this enzyme, RNA-guided Cas9 nuclease, to do precise metabolic engineering of polyploid Saccharomyces cerevisiae strains that have been widely used in the wine, beer, and fermentation industries.

The possibilities for improved nutritive value in foods are staggering, he said. "Wine, for instance, contains the healthful component resveratrol. With engineered yeast, we could increase the amount of resveratrol in a variety of wine by 10 times or more. But we could also add metabolic pathways to introduce bioactive compounds from other foods, such as ginseng, into the wine yeast. Or we could put resveratrol-producing pathways into yeast strains used for beer, kefir, cheese, kimchee, or pickles--any food that uses yeast fermentation in its production."

Another benefit is that winemakers can clone the enzyme to enhance malolactic fermentation, a secondary fermentation process that makes wine smooth. Improper malolactic fermentation generates the toxic byproducts that may cause hangover symptoms, he said.

Jin stressed the genome knife's importance as a tool that allows genetic engineers to make these extremely precise mutations.

"Scientists need to create designed mutations to determine the function of specific genes," he explained. "Say we have a yeast that produces a wine with great flavor and we want to know why. We delete one gene, then another, until the distinctive flavor is gone, and we know we've isolated the gene responsible for that characteristic."

The new technology also makes genetically modified organisms less objectionable, he said. "In the past, scientists have had to use antibiotic markers to indicate the spot of genetic alteration in an organism, and many persons objected to their use in foods because of the danger of developing antibiotic resistance. With the genome knife, we can cut the genome very precisely and efficiently so we don't have to use antibiotic markers to confirm a genetic event."

The research was reported in a recent issue of Applied and Environmental Microbiology.

Read the rest here:
Jailbreaking yeast could amp up wine's health benefits, reduce morning-after headaches

Recommendation and review posted by Bethany Smith

Atlanta, GA (PRWEB) March 16, 2015

African American women have higher death rates from breast cancer than do white women. Veena Rao, Ph.D., researcher, professor and co-director of the Cancer Biology Program in the department of OB/GYN at Morehouse School of Medicine, has pointed to multiple factors that contribute to the increased vulnerability of African American women, such as barriers to testing and quality of treatment. Leading medical researchers, including University of Washington geneticist and Lasker Laureate Mary-Claire King, highlight additional factors undetected inherited mutations and now recommend offering genetic testing for all women at about age 30. Dr. King will make a free, public address at the Morehouse School of Medicine on March 19, to discuss Inherited Breast Cancer: From Gene Discovery to Public Health.

Dr. Kings discovery in 1990 of the BRCA1 breast cancer gene demonstrated a mechanism of inherited cancer and proved that gene mutations could predict vulnerability to the disease.

A 2013 study of inherited predisposition to breast cancer among African American women by Dr. King and Dr. Olufunmilayo Olopade, director of The Center for Clinical Cancer Genetics, at the University of Chicago, found that 22 percent of African American breast cancer patients inherited a damaging mutation in BRCA1 or BRCA2 or another breast cancer gene. Women carrying a mutation of BRCA1 or BRCA2 have a greater than 80 percent lifetime risk of developing breast cancer, as compared with 11% for women without mutations.

Recently, Dr. King showed that women with BRCA1 or BRCA2 mutations had elevated risk for breast cancer, even if they have no family history of the disease. Therefore, she recommends that BRCA1 and BRCA2 testing be made available to all women.

I believe that every woman should be offered testing of BRCA1 and BRCA2 at about age 30 as part of routine medical care, said Dr. King. About half of women who inherit mutations in the BRCA1 or BRCA2 genes have no family history of breast or ovarian cancer and have no idea that they are carrying cancer-causing mutations. Affordable, accessible early detection is a public health priority for saving lives.

While some within the medical community voice caution that universal screening could lead to anxiety for some women, King and Olopade focus on the benefits. Having a genetic mutation doesnt mean youre definitely going to get cancer, Dr. Olopade told NPR last September. Women at greater risk should work with their doctors closely to make decisions about the best approach to reducing their chances of developing breast cancer.

Within the African American community, access to mammograms and other testing, as well as follow-up care continues to be a challenge. Disparities in availability of breast cancer care is a profound public health concern.

On March 19, Dr. King will give a special lecture, co-sponsored by the Albert and Mary Lasker Foundation and the Morehouse School of Medicine. In September 2014, the Lasker Foundation awarded Dr. King its prestigious Special Achievement Award in Medical Science for her bold, imaginative, and diverse contributions to medical science and human rights.

For more information on the availability of genetic screening in the Atlanta area, please see:

See the rest here:
Dr. Mary- Claire King to speak at Morehouse School of Medicine on how genetic screening for all women can lower risk ...

Recommendation and review posted by Bethany Smith

Analysis of large epidemiologic studies identifies rare variants associated with no preventive benefit

An analysis of genetic and lifestyle data from 10 large epidemiologic studies confirmed that regular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) appears to reduce the risk of colorectal cancer in most individuals. The study being published in the March 17 issue of JAMA found that a few individuals with rare genetic variants do not share this benefit. The study authors note, however, that additional questions need to be answered before preventive treatment with these medications can be recommended for anyone.

"Previous studies, including randomized trials, demonstrated that NSAIDS, particularly aspirin, protect against the development of colorectal cancer, but it remains unclear whether an individual's genetic makeup might influence that benefit," says Andrew Chan, MD, MPH, of the Massachusetts General Hospital (MGH) Gastroenterology Division, co-senior and co-corresponding author of the JAMA report. "Since these drugs are known to have serious side effects - especially gastrointestinal bleeding - determining whether certain subsets of the population might not benefit is important for our ability to tailor recommendations for individual patients."

The research team analyzed data from the Colon Cancer Family Registry and from nine studies included in the Genetics and Epidemiology of Colorectal Cancer Consortium - which includes the Nurses' Health Study, the Health Professionals Follow-up Study and the Women's Health Initiative - comparing genetic data for 8,624 individuals who developed colorectal cancer with that of 8,553 individuals who did not, matched for factors such as age and gender. The comprehensive information on lifestyle and general health data provided by participants in the studies again confirmed that regular use of aspirin or NSAIDs was associated with a 30 percent reduction in colorectal cancer risk for most individuals. However, that preventive benefit did not apply to everyone, and the study found no risk reduction in participants with relatively uncommon variants in genes on chromosome 12 and chromosome 15.

"Determining whether an individual should adopt this preventive strategy is complicated, and currently the decision needs to balance one's personal risk for cancer against concerns about internal bleeding and other side effects," states Chan, who is an associate professor of Medicine at Harvard Medical School. "This study suggests that adding information about one's genetic profile might help in making that decision. However, it is premature to recommend genetic screening to guide clinical care, since our findings need to be validated in other populations. An equally important question that also needs to be investigated is whether there are genetic influences on the likelihood that someone might be harmed by treatment with aspirin and NSAIDs."

###

The lead author of the JAMA report is Hongmei Nan, MD, PhD; formerly a research fellow at Brigham and Women's Hospital and now on the faculty at the Fairbanks School of Public Health and the Simon Cancer Center at Indiana University. Li Hsu, PhD, of the Fred Hutchinson Cancer Research Center is co-corresponding author, and Ulrike Peters, PhD, MPH, also of Fred Hutch, is co-senior author. Support for this study includes several grants from the National Cancer Institute and the National Institute for Diabetes and Digestive and Kidney Diseases.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $760 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See more here:
Genetic background determines whether aspirin/NSAIDS will reduce colorectal cancer risk

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise WASHINGTON Today AACC sent formal comments to the Food and Drug Administration (FDA) on the agencys proposed regulation of next-generation sequencing tests. AACC appreciates FDAs efforts to seek input from the healthcare community before developing new policy in this area, but is concerned that FDA regulation of next-generation sequencing could impede the advancement of precision medicine.

Precision medicine uses a persons unique biological makeup, including genetics, to determine which treatments that person would respond to best. Genetic tests hold the potential to predict an individuals risk of developing numerous different conditions throughout life. Having this knowledge could lead one to take a more proactive approach to his or her health, particularly with respect to chronic diseases such as cardiovascular disease and diabetes that could be prevented with basic lifestyle changes. Next-generation sequencing will enhance the application of precision medicine by making genetic testing more readily available.

After reviewing FDAs preliminary discussion paper on the topic, Optimizing FDAs Regulatory Oversight of Next-Generation Sequencing Diagnostic Tests, AACC recommends that oversight of next-generation sequencing remain under the Clinical Laboratory Improvement Amendments (CLIA) like other laboratory developed tests. CLIA-regulated laboratories conducting next-generation sequencing testing are experienced in developing, verifying, and performing clinical tests. AACC believes that CLIA-recognized accrediting bodies and professional societies should continue to take the lead in providing oversight and guidance for next-generation sequencing testing in the absence of specific, identified problems with this approach.

AACC agrees with the FDA that next-generation sequencing tests offer great opportunities for advancing laboratory medicine and improving patient care, and we commend the agencys efforts to initiate a dialogue among the various organizations and professionals involved in next-generation sequencing and those affected by such testing, said AACC President Dr. David D. Koch. We believe, however, that the current oversight mechanisms in place for next-generation sequencing are sufficient for dealing with the particular challenges this technology presents and that further FDA involvement at this time might hinder the advancement of this field.

Read AACCs comment letter here.

________________________________________

About AACC Dedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit http://www.aacc.org.

Here is the original post:
AACC Cautions FDA Against Over-Regulating the Genetic Testing Technology Vital to Precision Medicine

Recommendation and review posted by Bethany Smith

KIDLINGTON, England, March 17, 2015 /PRNewswire/ --

Diagnosis and Drug Delivery for diseases like cancer, cardiovascular and genetic ailments have always been a concern. In recent years, however, new strides and developments in the Nano-Medicine Market have facilitated more effective diagnosis and drug delivery for diseases. Not only can these diseases now be studied better but it will also help us in making informed decisions producing better cures. The Nano-medicine market is on a steady growth and with a compound annual growth rate (CAGR) of 12.5% from 2011, the market size will reach to $130.9 billion by 2016.

Nanotechnologies in Drug Delivery Congress organized by MarketsandMarkets Conferences are gathering Industry Experts from the Nano-Medicine Market who will look at these developments and also present new ideas. Supported by the French Society for Nanomedicine, the congress will beheld on 27 - 28 April 2015 inLondon, UK.

Register for the Event:http://www.mnmconferences.com/nanotechnologies_attend-conference.html

Save 20% off on the Delegate Registration if you register your seat before March! Just use WM/ND/20 as a discount code. So hurry to get an amazing deal!

Speaking at the congress will be AstraZeneca, Nemaura Pharma, Lloyds Register Quality Assurance, Cytoviva, World Nano Foundation, King's College London, Institute for Biological and Medical Imaging, Uppsala University and University of Oxford among others.

One of the Key Speakers at the Congress will be Prof. Andrew Owen, Professor of Molecular and Clinical Pharmacology at University of Liverpool and Chair atBritish Society for Nano medicine, Liverpool - UK. He will be delivering a special address on day one on nanotechnology - enabled drug delivery in HIV therapy. Prof. Owen holds a personal Chair in the Department of Molecular and Clinical Pharmacology at the University of Liverpool, UK and has contributed to over 120 original research and review publications, book chapters and patent applications. Shedding light on the topic he said, "Nanotechnology-based HIV drug delivery has attracted recent attention within academia with many technologies in early stage evaluation for improving oral bioavailability or targeting HIV-infected cells and tissues. Interest has been significantly accelerated recently by the entry of long-acting Nano formulations into human trials. These Nano formulations developed by Janssen Pharmaceuticals and ViiV Healthcare are able to sustain therapeutic concentrations in blood for over 1 month from a single intramuscular depot injection."

For More Details Visit: http://www.mnmconferences.com/nanotechnologies.html

Prof. Owen believes nanotechnology - enabled drug delivery will positively influence future treatments of HIV patients. He stated, "Modern antiretroviral therapy has significantly improved morbidity and mortality but patient adherence to medication is an on-going issue that frequently results in treatment failure. Also, many antiretroviral drugs exhibit poor bioavailability and adverse drug reactions are common. The ability to administer drugs monthly rather than daily at lower overall doses may mitigate issues with adherence and pill fatigue, which will hopefully translate to improved patient outcomes."

Other topics that will be covered at the congress include the role of Nanomedicine and targeted medicine for personalized medicine, real-time, whole body, tracking of nanoparticle bio-distribution using multispectral optoacoustic tomography, targeted Nanomedicine in cancer therapy and combining diagnostics and delivery in a single device. The congress will be a great opportunity for delegates to learn about the new developments and also interact with global industry peers.

Read more:
Nano-Medicine Market Size is Expected to be Worth $130.9 Billion by 2016

Recommendation and review posted by Bethany Smith

Human Molecular Genetics : The severity of retinal pathology in homozygous Crb1rd8/rd8 mice...
The severity of retinal pathology in homozygous Crb1rd8/rd8 mice is dependent on additional genetic factors. Ulrich F.O. Luhmann et al (2015), Human Molecula...

By: KeSimpulan

More:
Human Molecular Genetics : The severity of retinal pathology in homozygous Crb1rd8/rd8 mice... - Video

Recommendation and review posted by Bethany Smith

The Sims 3 - Perfect Genetics Challenge - Pt7 - The brother and the stripper
If you like this video please leave a thumbs up, it really helps Open fully for *NEW SCHEDULE* info and social media links Weekly Schedule (Subject t...

By: xSimSugar

See the original post:
The Sims 3 - Perfect Genetics Challenge - Pt7 - The brother and the stripper - Video

Recommendation and review posted by Bethany Smith

Spring Fling Genetics Conference Breeder Panel

By: HolsteinWorld MOOTUBE

Read more here:
Spring Fling Genetics Conference Breeder Panel - Video

Recommendation and review posted by Bethany Smith

So you lost your job and your lifes a mess. Youre fat, youre broke, youre bad at sex. Youre looking at your dog, hoping she doesnt die next. You need to get lucky. And whats the best way to get lucky? No, its not finding a four-leafed clover on St. Patricks Day. That kind of luck doesnt exist. No, what you need to do is go impress a bunch of drunk strangers with your knowledge of four-leaf clover genetics!

Like every other trait on every other living thing, a clovers lucky fourth leaf sprouts from DNA. But the clover genome is surprisingly complicated, and finding the genes responsibleand under what conditionsfor the four-leaf mutation is a still-unsolved biological puzzle.

There are over 300 different species of clover, but the type most associated with the rare fourth lucky leaf is the widespread white clover (so named because of the fluffy, delicious-looking white blossoms). Its like having a cat with an extra claw. We know it has a genetic basis, and a mutation that happens at a slow but regular frequency, says Wayne Parrott, who studies crop genetics at the University of Georgia. His lab has come closest to finding the genetic roots of the four-leaf mutation. We know more or less where it is on the chromosome, he says. But the clover seems to have done everything possible to make its genome inscrutable.

This is partly because the plant is so widely distributed. Native on three continents, the white clovers genome tells the story of a plant that geography tried, and failed, to split into multiple species. The white clover is an allotetrapoloid. Huh? Best to work backward on that one. -Ploid means chromosome, and -tetra means four. That means the white clover has double the amount of chromosomes as humans, mangoes, pill bugs, and most other organisms. This brings us to the allo- prefix, which means that each pair of the white clovers chromosomes comes from a different species.

Crazy, I knowbut clover arent aliens. When itwas proliferating over the globe, the clover started to split into multiple species, but then theydoubled back and started breeding again. And instead of recombining into diploid chromosomes, the clover kept both pairs. Maize and sorghum had some awkward allotetraploid years when they first started splitting about 20 million years ago (both now have just two chromosomes). Pretty exciting family life for a boring ole ground cover, right?

On top of that,white clover dont have the tidiest genealogies. The plants are promiscuous outbreeders (opposite of inbreeders, sorry Team Lannister). In fact, they are pretty much incapable of breeding with themselves (as many plants do). Combined with the quadruple chromosomes, the white clovers sex life means that it is incredibly difficult to figure out which genes came from which parent. This means inheritance studieswhich figure out if a genes expression is due to nature over nurtureare all but impossible.

But Parrotts group made an admirable accomplishment. They grew 178 plants and recordedamong other leaf traits like pattern and colorany plants with at least one four-leafed stem (A single clover plant sends out many runners). In the study, four-leafed stems favored warm conditionsthere were double the amount of outdoor four-leaf clovers in the summer than winter. And in the winter, more lucky shamrocks grew in the greenhouse than outside.

This could mean that three leaves is an adaption for colder or wetter climates. Clovers are a member of the bean family, which Parrott says have been steadily losing leaves over the millennia. If you go back, the ancestors of the bean family had a lot more leaves, he says. In the case of beans and clover, you are down to three. He says that this could be accidental, though says it is noteworthy that if having more leaves were a big advantage, then youd expect to see more of them. But, he also says that the number of leaves could be entirely accidental. Not everything happens for a reason, he says.

With their experimental data in hand, Parrotts teamstarted looking at the genome. They found at least one gene that correlated closely to the expression of three leaves. These genes were similarly somewhat suppressed in the summer months, leading to more four leaf clovers. Weather is important for a lot of plant traits, says Parrott, though hes reluctant to say it all comes down to time of year. He says one of the reasons that we see more four leafed clovers when its warm is because the plant is making more leaves in those times of year. The probability is simply higher.

And clovers can grow many more than four leavesthe Guinness record is 56 leaves on a single stem. Speaking of Guinness, if you drink enough of it today* youre sure to find plenty of six-leaf clovers, at the very least.

See more here:
The Mysterious Genetics of the Four-Leaf Clover

Recommendation and review posted by Bethany Smith

Science Advances : Gene therapy rescues disease phenotype in a spinal muscular atrophy......
Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model. Monica Nizzardo et al (2015), Scie...

By: KeSimpulan

Visit link:
Science Advances : Gene therapy rescues disease phenotype in a spinal muscular atrophy...... - Video

Recommendation and review posted by Bethany Smith

MIAMI (PRWEB) March 17, 2015

GlobalStemCellsGroup.com has announced plans to participate in the 25th annual Argentine Congress of Aesthetic Medicine April 9 and 10 2015. More than 1,000 physicians from around the world will descend on Buenos Aires for the conference to learn and share new findings in aesthetic medicine.

Following the congress, Global Stem Cells Group and Estanislao Janowski, M.D., a plastic surgeon specializing in stem cell application in aesthetic and cosmetic medicine will conduct an intensive, hands-on course on stem cell harvesting, isolation and re-integration, to be held April 11. Janowski, a GSCG faculty member and long-time collaborator is the owner and president of Bioplastica, an aesthetic surgical center featuring the latest stem cell applications in cosmetic and anti-aging medicine.

This will be the third year Global Stem Cells Group participates in the conference, hosted by the Argentina Society of Aesthetic Medicine (SOARME). A soon-to-be-named GSCG faculty member will also deliver a keynote speech to congress attendees.

The international event, which will be held at the Catholic University of Argentina in Buenos Aires, will feature acclaimed stem cell aesthetic practitioners from Argentina and the U.S. SOAME is a member of the Argentine Medical Association (A.M.A.) and of the International Union of Aesthetic Medicine (U.I.M.E.). SOAME has the scientific support of the John F. Kennedy University in Buenos Aires and a host of national and international scientific organizations.

For more information visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

View post:
Global Stem Cells Group to Participate in the 25th Argentine Congress of Aesthetic Medicine in Buenos Aires April 9-10 ...

Recommendation and review posted by simmons

Orange, California (PRWEB) March 17, 2015

The top stem cell therapy clinics in California, Telehealth, are now offering treatment for nonhealing wounds at three locations. The stem cell therapy for wound healing is being offered by Board Certified doctors at three separate locations in Orange, La Jolla and Upland. Call (888) 828-4575 for more information and scheduling.

Patients with diabetes, neuropathy and autoimmune disorders often find it difficult to heal even minor wounds. This may lead to diabetic ulcers and infections in the soft tissue and/or bone. At times, even the most rigorous conventional wound care fails to heal wounds sufficiently.

At Telehealth, stem cell therapy for nonhealing wounds has been showing exceptional results. Wounds that had basically been unresponsive to traditional methods have displayed quick results with healing when the procedures are performed. The regenerative medicine treatments involve either bone marrow derived stem cells or amniotic derived stem cells. Additional, PRP therapy is included in the treatment at times when necessary.

Along with helping to heal difficult wounds, stem cell therapy is also available for degenerative arthritis, chronic tendonitis, rotator cuff tears, ligament injuries, migraines and much more. Treatments are offered in Orange, Upland and a new La Jolla location by Board Certified doctors with extensive experience.

Most treatments are partially covered by insurance, which helps considerably to keep cost down. Call (888) 828-4575 for more information and scheduling.

More here:
Stem Cell Therapy Now Being Offered for NonHealing Wounds at Telehealth's Three Regenerative Medicine Clinics

Recommendation and review posted by simmons

Spinal Cord Injury Spotlight - Dominic P. at Project Walk San Francisco
Dominic Prado suffered a C6 spinal cord injury in January of 2012. He has always made his recovery program a priority with weekly training sessions. His rece...

By: Project Walk

Read more from the original source:
Spinal Cord Injury Spotlight - Dominic P. at Project Walk San Francisco - Video

Recommendation and review posted by sam

A TEENAGER'S quest to find a bone marrow match and beat his leukaemia has inspired school friends to go on to save the lives of two perfect strangers.

Jack Coen and Joe Rowbottom, both 18, were at Bradford Grammar School when fellow pupil Alex Anstess, now 16, was first diagnosed with Acute Myeloid Leukaemia in 2012.

After hearing a talk in school about registering on the Anthony Nolan Bone Marrow register, they - and others - signed up and both of them have gone on to successfully donate stem cells.

Jack, from Ilkley, who donated in October last year after being found to be a perfect match for a patient needing a bone marrow transplant, said: I just thought if you have the opportunity to save someones life then why not? If I was in that position, Id want someone to do it for me.

"On the day, I thought about the other person receiving my stem cells and hoped I could give them more Christmases with their family. If I never make another good decision for the rest of my life, I have at least made one good and worthwhile decision by donating."

And Joe, from Yeadon, who donated his stem cells last month, said: It was so easy to spit in a tube and sign up. It was weird to think a stranger was dependent on me and yet its such a small thing to do. It was actually surprising something so simple could save someones life. Knowing Alex spurred me on to donate because I knew what the person was going through. Its great to see Alex back at school and proves the donor register does work.

Although Alex, of Cullingworth, had gone into remission after his 2012 diagnosis, the cancer returned in July last year and doctors broke the news that his life depended on a bone marrow transplant. It was The Anthony Nolan Trust that found him a perfect match and he had the procedure in September last year, helping him on the road to recovery.

His mum, Sue, said: I cannot describe the feeling of seeing that little bag of stem cells come in for Alex. We waited a long time for that moment and Ill never forget the relief we felt. Were so thankful to the donor who literally saved his life. Its absolutely brilliant that Jack and Joe have gone on to donate and help another family like ours."

Bradford Grammar headteacher Kevin Riley said: The school motto is Hoc Age which we usually translate as Just do it. What a wonderful example Jack and Joe are of that determination to help others. Im proud of them and the other students who have responded to the appeal.

If you are aged 16-30 and in good health you too can sign up to the Anthony Nolan register at anthonynolan.org. To find out more about the Register & Be a Lifesaver programme, email registerandbe@AnthonyNolan.org or call 0207 284 8213.

Here is the original post:
Teenager's quest to beat leukaemia inspires school friends to donate stem cells to help people in need

Recommendation and review posted by Bethany Smith

A little boy with an extremely rare condition is in desperate need of a transplant to save his life.

Finn McEwen, seven, from Litherland has bone marrow failure and now his family are facing a race against time to find a stem cell match.

His condition, myelodysplastic syndrome, is extremely rare in children and cannot be treated with chemotherapy, so a transplant is Finns only hope.

His family, including dad Neil, 46, baby sister Seren, 18 months, and brother Lucas, 6, have all been ruled out as matches and Finn needs to have the transplant within the next six to eight weeks to have the best chance of recovery.

His mum Carole, 43, told the Liverpool Echo Finn has always been well and active, and it was a massive shock when doctors said he had the condition.

The family had to endure weeks of waiting after Finn suffered a serious nosebleed in January before doctors could find out what was wrong with him, as it is extremely difficult to diagnose.

Cry for help: A transplant is the only cure for the condition, which is caused by bone marrow not making enough healthy red blood cells

Carole said: Its been this massive rollercoaster, up and down. We couldnt believe it, it came from nowhere. We thought it was nothing and then thought it could be leukaemia, and then we had that couple of weeks where we thought it was going to be OK.

This is a hundred times worse than before. Every time we go in there seems to be an extra bit of bad news. It just feels like its your worst nightmare.

A transplant is the only cure for the condition, which is caused by bone marrow not making enough healthy red blood cells, white blood cells and platelets.

See the original post here:
Finn McEwen: Family's bone marrow appeal to help save seven-year-old with rare condition

Recommendation and review posted by Bethany Smith

Stem cells are special cells that can turn into any kind of cells in the body. They serve as a repair system for the body. There are two main types of human stem cells: embryonic stem cells and adult stem cells.

Embryonic stem cells are cells that come from an unborn baby (embryo). Those are NOT the cells that are used for this product.LUMINESCEformulation uses technology derived from the study of Adult Stem Cells.

Stem cells communicate with tissue cells to induce repair. They produce many different growth factors and "communication" chemicals to do this.Dr Nathan Newmanhas been able to take stem cells in the lab, and separate them from the solution that holds the growth factors. This media is the foundation of theLUMINESCEproduct.

What is the relationship between growth factors and the stem cell technology?

The patent-pending technology ofLUMINESCEprovides for the delivery of key growth factors found in natural skin. As we age, the production of these growth factors within skin is reduced, and leads to wrinkling and thinning of the skin. By re-introducing these factors through the daily application ofLUMINESCE, damaged skin cells may be repaired, and skin tissue re-generated.

Stem cells are cells that have the ability to grow into any kind of cell in the body, and they rely on special signals to tell them what cells they will ultimately become. If you know the stem cell language, then you could communicate to the cells.

In this way, you could have stem cells that become new young skin cells, rebuild collagen, and deliver a new younger looking skin.

Continue reading here:
Stem Cells, Skin Care and Dr Newman | Skin Care

Recommendation and review posted by Bethany Smith

Steve Perrin, Ph.D., CEO and CSO, discusses why iPS technology is ready for drug discovery for today's ALS patients. Click here to learn why Steve believes TDI is uniquely suited to implement this technology in ALS research.

Fernando Vieira, M.D., director of research operations, discusses how iPS technology can be used to model sporadic ALS, help to identify sub-types of ALS patients and accelerate drug development as part of a comprehensive translational research program at ALS TDI.

Jessie St. Martin, associate scientist, talks about induced pluripotent stem cells (iPS cells) and their importance in ALS research. Jessie, a recent addition to the translational research team, will play an integral part in developing this program at ALS TDI. Click here to learn more about iPS cells.

Jenny Dwyer, board member, explains why your support of the iPS program at ALS TDI may have the ability to rapidly accelerate treatments for today's patients. Jenny was a longtime ALS caregiver of her husband, Pat. Together, they were advocates for ALS research. Click here to listen to her message.

Continue reading here:
Invest in iPS @ TDI | ALS Therapy Development Institute

Recommendation and review posted by Bethany Smith

Nova Cells Institute treatment Report, stem cell therapy, 562-916-3410
Nova Cells Institute stem cell treatment report shows success with spina bifida, lewy body dementia, cancer patients and more - visit http://www.novacellsinstitute.com to learn more.

By: NCIM

Link:
Nova Cells Institute treatment Report, stem cell therapy, 562-916-3410 - Video

Recommendation and review posted by Bethany Smith